Cover Image

Setting priorities in the health care sector – the case of oral anticoagulants in nonvalvular atrial fibrillation in Denmark

Peter Bo Poulsen,1 Søren Paaske Johnsen,2 Morten Lock Hansen,3 Axel Brandes,4 Steen Husted,5,&dagger; Louise Harboe,6 Lars Dybro7 1Pfizer Denmark ApS, Ballerup, 2Department of Clinical Epidemiology, Aarhus University Hospital, 3Department of Cardiology, Zealand University Hospital, Ro...

Full description

Saved in:

Bibliographic Details
Main Authors:	Poulsen PB (Author), Johnsen SP (Author), Hansen ML (Author), Brandes A (Author), Husted S (Author), Harboe L (Author), Dybro L (Author)
Format:	Book
Published:	Dove Medical Press, 2017-10-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Features of Modern Anticoagulant Therapy in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease
by: I. S. Daabul, et al.
Published: (2016)

A cross-sectional study of appropriateness evaluation of anticoagulation therapy for inpatients with nonvalvular atrial fibrillation
by: Xiao-Yuan Zheng, et al.
Published: (2023)

Anticoagulation control among patients with nonvalvular atrial fibrillation: A single tertiary cardiac center experience
by: Shaban Mohammed, et al.
Published: (2017)

Efficiency of the Left Atrial Appendage Thrombus Dissolution in Patients with Persistent Nonvalvular Atrial Fibrillation with Warfarin or Direct Oral Anticoagulants Therapy
by: E. S. Mazur, et al.
Published: (2021)

ANTITHROMBOTIC THERAPY IN NONVALVULAR ATRIAL FIBRILLATION: PROBLEMS AND PROSPECTS
by: A. Y. Rychkov, et al.
Published: (2016)

Efficacy and Safety of Direct Oral Anticoagulants in Patients with Diabetes and Nonvalvular Atrial Fibrillation: Meta-Analysis of Observational Studies
by: Bo Cao, et al.
Published: (2021)

Predictors of Thrombus Dissolution in the Left Atrial Appendage in Patients with Persistent Nonvalvular Atrial Fibrillation
by: E. S. Mazur, et al.
Published: (2022)

Elderly Bleeding Risk of Direct Oral Anticoagulants in Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Cohort Studies
by: Jessika Lobraico-Fernandez, et al.
Published: (2019)

New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness
by: Mani H, et al.
Published: (2014)

Anticoagulation Therapy by Age and Embolic Risk for Nonvalvular Atrial Fibrillation in Mexico, an Upper-Middle-Income Country: The CARMEN-AF Registry
by: Manlio F. Márquez, et al.
Published: (2020)

EFFICACY AND SAFETY OF DIRECT ORAL ANTICOAGULANTS IN THE PREVENTION OF STROKE IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION IN EVERYDAY CLINICAL PRACTICE: FACTS ABOUT RIVAROXABAN
by: I. S. Yavelov
Published: (2016)

Incidence of cerebral microembolization in patients with nonvalvular atrial fibrillation using transcranial Doppler
by: Hamouda A.K.H El-Bahnasy, et al.
Published: (2022)

Healthcare resources and costs associated with nonvalvular atrial fibrillation in Spain: apixaban versus acenocoumarol
by: Josep Comin Colet, et al.
Published: (2023)

Costs of major intracranial, gastrointestinal and other bleeding events in patients with atrial fibrillation - a nationwide cohort study
by: Marie Jakobsen, et al.
Published: (2017)

Erratum to: costs of major intracranial, gastrointestinal and other bleeding events in patients with atrial fibrillation - a nationwide cohort study
by: Marie Jakobsen, et al.
Published: (2017)

Type 2 diabetes mellitus and nonvalvular atrial fibrillation in Mexico: national registries raise a red flag
by: Manlio F. Márquez-Murillo, et al.
Published: (2023)

Body Mass Index Influence on the Clinical Outcomes for Nonvalvular Atrial Fibrillation Patients Admitted to a Hospital Treated with Direct Oral Anticoagulants: A Retrospective Cohort Study
by: Li X, et al.
Published: (2021)

Antithrombotic therapy and clinical characteristics of patients hospitalized for nonvalvular atrial fibrillation in Galician internal medicine clinics
by: Jose Manuel Cerqueiro-Gonzelez, et al.
Published: (2019)

Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US
by: Miller JD, et al.
Published: (2016)

The preoperative management of dabigatran and its specific antidote idarucizumab in patients with nonvalvular atrial fibrillation: Case reports
by: Tomić Milan
Published: (2020)

Estimation of left atrial appendage wall motion velocity in patients with persistent nonvalvular atrial fibrillation and its effect on thrombotic risk
by: Waleed Yousof, et al.
Published: (2021)

Algorithm for the Choice of Anticoagulant for Patients with Atrial Fibrillation
by: Yu. P. Skirdenko, et al.
Published: (2020)

The Anticoagulation in Patients with Atrial Fibrillation: Rivaroxaban and Warfarin
by: I. Yu. Koroleva, et al.
Published: (2016)

Newer Anticoagulants for Non-Valvular Atrial Fibrillation
by: Joseph M. Harburger, et al.
Published: (2012)

Clinical Efficacy and Safety Comparison of Rivaroxaban and Dabigatran for Nonvalvular Atrial Fibrillation Patients Undergoing Percutaneous Left Atrial Appendage Closure Operation
by: Xiaoye Li, et al.
Published: (2021)

DABIGATRAN ETEXILATE FOR PREVENTION OF CARDIOEMBOLIC COMPLICATIONS IN NONVALVULAR ATRIAL FIBRILLATION: HOW TO DO THE INTERVENTION MORE EFFECTIVE AND SAFER
by: I. S. Yavelov
Published: (2016)

Topical issues of dabigatran use in combination antithrombotic therapy in patients with acute coronary syndrome and nonvalvular atrial fibrillation
by: N. A. Novikova, et al.
Published: (2020)

THROMBUS OF LEFT ATRIUM AND/OR ITS APPENDAGE IN CASE OF NONVALVULAR ATRIAL FIBRILLATION: FREQUENCY OF DETECTION AND CLINICAL RISK FACTORS
by: I. A. Zaigrayev, et al.
Published: (2020)

Usability of an Atrial Fibrillation Anticoagulation Decision-Support Tool
by: Mark L. Wess MD, SM, et al.
Published: (2011)

Thrombus of left atrium and/or its appendage in nonvalvular atrial fibrillation: echocardiographic and laboratory risk factors, capabilities for prediction and correction
by: I. A. Zaigraev, et al.
Published: (2020)

Anticoagulation therapy in atrial fibrillation after intracranial hemorrhage
by: A. S. Gerasimenko, et al.
Published: (2021)

Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation
by: Turpie AGG
Published: (2014)

Cost considerations in the management of atrial fibrillation – impact of dronedarone
by: Khaykin Y, et al.
Published: (2012)

Evaluation of Remote Pharmacist-Led Outpatient Service for Geriatric Patients on Rivaroxaban for Nonvalvular Atrial Fibrillation During the COVID-19 Pandemic
by: Xiaoye Li, et al.
Published: (2020)

Effectiveness and safety of edoxaban versus warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies
by: Mohammed M. Alsultan, et al.
Published: (2023)

THE RISK OF BLEEDINGS IN PATIENTS WITH ATRIAL FIBRILLATION DURING ANTICOAGULANT THERAPY
by: M. Yu. Gilyarov
Published: (2015)

Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Renal Dysfunction
by: Z. D. Kobalava, et al.
Published: (2021)

THE RISK OF BLEEDINGS IN PATIENTS WITH ATRIAL FIBRILLATION DURING ANTICOAGULANT THERAPY
by: M. Yu. Gilyarov
Published: (2015)

Treated with preventive anticoagulation therapy in atrial fibrillation: The patients' perspective
by: Karin Olsson, et al.
Published: (2022)

Efficacy and Safety of Rivaroxaban, Apixaban, and Edoxaban for Nonvalvular Atrial Fibrillation Based on Blood Coagulation Activity and Drug Plasma Concentration: SETtsu and North Osaka Multicenter Direct Oral AntiCoagulant (SET DOAC) Registry
by: Michihiro Suwa, et al.
Published: (2024)